{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:07Z","timestamp":1790753827618,"version":"4.1.0"},"reference-count":48,"publisher":"Impact Journals, LLC","issue":"60","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,11,5]]},"DOI":"10.18632\/oncotarget.27237","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T15:16:33Z","timestamp":1572966993000},"page":"6403-6417","source":"Crossref","is-referenced-by-count":31,"title":["Volasertib preclinical activity in high-risk hepatoblastoma"],"prefix":"10.18632","volume":"10","author":[{"given":"Dina","family":"Kats","sequence":"first","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora A.","family":"Ricker","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah E.","family":"Berlow","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Noblet","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Nicolle","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Mevel","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Branchereau","sequence":"additional","affiliation":[{"name":"Bic\u00eatre Hospital, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Gabriel","family":"Judde","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody D.","family":"Stiverson","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Stiverson","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Svalina","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teagan","family":"Settelmeyer","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Matlock","sequence":"additional","affiliation":[{"name":"Omics Data Automation, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Lathara","sequence":"additional","affiliation":[{"name":"Omics Data Automation, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mussini","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Geller","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Noakes","sequence":"additional","affiliation":[{"name":"Champions Oncology, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Sloma","sequence":"additional","affiliation":[{"name":"Champions Oncology, Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Bharathy","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[{"name":"Research and Development Unit, XenTech, Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Keller","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Therapy Development Institute, Beaverton, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/pbc.24215","article-title":"The epidemiology of hepatoblastoma","volume":"59","author":"Birch","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1053\/jpsu.2001.22953","article-title":"Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma","volume":"36","author":"Bensoussan","year":"2001","journal-title":"J Pediatr Surg"},{"key":"3","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.21873\/anticanres.11143","article-title":"Therapeutic Innovations for Targeting Hepatoblastoma","volume":"36","author":"Berger","year":"2016","journal-title":"Anticancer Res"},{"key":"4","doi-asserted-by":"publisher","first-page":"e22620","DOI":"10.4161\/onci.22620","article-title":"Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma","volume":"2","author":"Fuchs","year":"2013","journal-title":"Oncoimmunology"},{"key":"5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-018-0145-8","article-title":"Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts","volume":"6","author":"Volinia","year":"2018","journal-title":"Biomark Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/or.2018.6793","article-title":"Targeting LRH\u20111 in hepatoblastoma cell lines causes decreased proliferation","volume":"41","author":"Vasudevan","year":"2019","journal-title":"Oncol Rep"},{"key":"7","doi-asserted-by":"publisher","first-page":"22665","DOI":"10.18632\/oncotarget.25205","article-title":"Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma","volume":"9","author":"Beierle","year":"2018","journal-title":"Oncotarget"},{"key":"8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrm3819","article-title":"Polo-like kinases: structural variations lead to multiple functions","volume":"15","author":"Bettencourt-Dias","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1242\/jcs.107.6.1509","article-title":"Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5","volume":"107","author":"Nigg","year":"1994","journal-title":"J Cell Sci"},{"key":"10","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1073\/pnas.0812135106","article-title":"Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay","volume":"106","author":"Lee","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/jpet.114.221150","article-title":"Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia","volume":"352","author":"Reschke","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"12","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1158\/1535-7163.MCT-09-0365","article-title":"Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas","volume":"8","author":"Dunn","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"13","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1038\/sj.onc.1207782","article-title":"Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas","volume":"23","author":"Ando","year":"2004","journal-title":"Oncogene"},{"key":"14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","article-title":"Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment","volume":"8","author":"Liu","year":"2015","journal-title":"Transl Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/leu.2014.222","article-title":"Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy","volume":"29","author":"Sch\u00f6ffski","year":"2015","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Adolf","year":"2009","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics","volume":"15","author":"Ahmad","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"18","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma\u2014a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zimmermann","year":"2012","journal-title":"Eur J Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hep.28621","article-title":"Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management","volume":"64","author":"Brugi\u00e8res","year":"2016","journal-title":"Hepatology"},{"key":"20","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.3390\/molecules20046113","article-title":"Thapsigargin--from Thapsia L. to mipsagargin","volume":"20","author":"Simonsen","year":"2015","journal-title":"Molecules"},{"key":"21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hep.29672","article-title":"New insights into diagnosis and therapeutic options for proliferative hepatoblastoma","volume":"68","author":"Taque","year":"2018","journal-title":"Hepatology"},{"key":"22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccr.2008.11.002","article-title":"Hepatic stem-like phenotype and interplay of Wnt\/beta-catenin and Myc signaling in aggressive childhood liver cancer","volume":"14","author":"Levillayer","year":"2008","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"publisher","first-page":"38347","DOI":"10.1038\/srep38347","article-title":"Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma","volume":"6","author":"Sindhi","year":"2016","journal-title":"Sci Rep"},{"key":"24","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","article-title":"Hep G2 is a hepatoblastoma-derived cell line","volume":"40","author":"Knowles","year":"2009","journal-title":"Hum Pathol"},{"key":"25","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"Smyth","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Chintagumpala","year":"2017","journal-title":"Hepatology"},{"key":"27","first-page":"2476","article-title":"Volasertib suppresses the growth of human hepatocellular carcinomaand","volume":"6","author":"Shi","year":"2016","journal-title":"Am J Cancer Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2014.07.020","article-title":"Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1","volume":"9","author":"Strebhardt","year":"2015","journal-title":"Mol Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1038\/bjc.2014.195","article-title":"A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies","volume":"110","author":"Yang","year":"2014","journal-title":"Br J Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1023\/A:1013157727506","article-title":"Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks","volume":"12","author":"Locker","year":"2001","journal-title":"Ann Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10637-015-0223-9","article-title":"Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity","volume":"33","author":"Sch\u00f6ffski","year":"2015","journal-title":"Invest New Drugs"},{"key":"32","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/cas.12814","article-title":"Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia","volume":"106","author":"Naoe","year":"2015","journal-title":"Cancer Sci"},{"key":"33","unstructured":"Boehringer Ingelheim. ID NCT01971476. Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01971476."},{"key":"34","doi-asserted-by":"publisher","first-page":"78452","DOI":"10.18632\/oncotarget.19632","article-title":"Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia","volume":"8","author":"Kiyoi","year":"2017","journal-title":"Oncotarget"},{"key":"35","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1200\/JCO.2007.11.6103","article-title":"Phase II trial of irinotecan in children with refractory solid tumors: a Children\u2019s Oncology Group Study","volume":"25","author":"Blaney","year":"2007","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/08880018.2014.909913","article-title":"Vincristine and irinotecan in children with relapsed hepatoblastoma: a single-institution experience","volume":"32","author":"Chang","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/aps.2012.44","article-title":"Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors","volume":"33","author":"Cheng","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"38","doi-asserted-by":"publisher","first-page":"10497","DOI":"10.18632\/oncotarget.24041","article-title":"The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells","volume":"9","author":"Sulman","year":"2018","journal-title":"Oncotarget"},{"key":"39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2018.12.012","article-title":"Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma","volume":"445","author":"Henssen","year":"2019","journal-title":"Cancer Lett"},{"key":"40","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbcan.2010.06.003","article-title":"Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity","volume":"1806","author":"Baranello","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2012.09.002","article-title":"Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors","volume":"1835","author":"Kaina","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5500\/wjt.v4.i4.294","article-title":"Role of liver transplantation in the management of hepatoblastoma in the pediatric population","volume":"4","author":"Goss","year":"2014","journal-title":"World J Transplant"},{"key":"44","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1097\/MPH.0b013e31821f0eaf","article-title":"Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin","volume":"33","author":"Nathan","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/sj.bjc.6601383","article-title":"Infertility rates following POMB\/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study","volume":"89","author":"Seckl","year":"2003","journal-title":"Br J Cancer"},{"key":"46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Clavell","year":"2012","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OTT.S60762","article-title":"Volasertib for AML: clinical use and patient consideration","volume":"8","author":"Kota","year":"2015","journal-title":"Onco Targets Ther"},{"key":"48","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.18632\/oncotarget.3538","article-title":"PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins","volume":"6","author":"Cassinelli","year":"2015","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T17:07:57Z","timestamp":1664816877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":48,"journal-issue":{"issue":"60","published-print":{"date-parts":[[2019,11,5]]}},"alternative-id":["27237","31741706"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27237","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,5]]}}}